×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RVNC – revance therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RVNC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/6
08:30 pm
rvnc
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
Neutral
Report
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
1/6
06:00 pm
rvnc
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
Low
Report
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
1/6
04:37 pm
rvnc
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
Low
Report
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
1/6
02:15 pm
rvnc
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
Low
Report
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
1/6
02:00 pm
rvnc
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
1/6
12:30 pm
rvnc
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
Low
Report
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
1/6
11:39 am
rvnc
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Low
Report
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
1/6
11:30 am
rvnc
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Low
Report
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Date
Time
Symbol
Company Name
Action
%Chg
8/8/2024
04:05 pm
RVNC
revance therapeutics, inc.
BEAT
Report
19.7%
revance therapeutics, inc.
5/9/2024
04:06 pm
RVNC
revance therapeutics, inc.
BEAT
Report
-22.6%
revance therapeutics, inc.
2/28/2024
04:05 pm
RVNC
revance therapeutics, inc.
BEAT
Report
26.1%
revance therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/6
09:01 am
rvnc
Form SCHEDULE 13D/A Revance Therapeutics, Filed by: Teoxane SA
Low
Report
Form SCHEDULE 13D/A Revance Therapeutics, Filed by: Teoxane SA
1/3
04:34 pm
rvnc
Form 4 Revance Therapeutics, For: Dec 31 Filed by: Schilke Tobin
High
Report
Form 4 Revance Therapeutics, For: Dec 31 Filed by: Schilke Tobin
1/3
04:34 pm
rvnc
Form 4 Revance Therapeutics, For: Dec 31 Filed by: Foley Mark J
High
Report
Form 4 Revance Therapeutics, For: Dec 31 Filed by: Foley Mark J
1/2
04:45 pm
rvnc
Form SC TO-T/A Revance Therapeutics, Filed by: Crown Laboratories, Inc.
Low
Report
Form SC TO-T/A Revance Therapeutics, Filed by: Crown Laboratories, Inc.
1/2
04:37 pm
rvnc
Form SC 14D9/A Revance Therapeutics, Filed by: Revance Therapeutics, Inc.
Low
Report
Form SC 14D9/A Revance Therapeutics, Filed by: Revance Therapeutics, Inc.
12/19
09:01 am
rvnc
Form SCHEDULE 13D/A Revance Therapeutics, Filed by: Teoxane SA
Low
Report
Form SCHEDULE 13D/A Revance Therapeutics, Filed by: Teoxane SA
12/12
08:02 am
rvnc
Form SC 14D9 Revance Therapeutics, Filed by: Revance Therapeutics, Inc.
Low
Report
Form SC 14D9 Revance Therapeutics, Filed by: Revance Therapeutics, Inc.
12/12
07:16 am
rvnc
Form SC TO-T Revance Therapeutics, Filed by: Crown Laboratories, Inc.
Low
Report
Form SC TO-T Revance Therapeutics, Filed by: Crown Laboratories, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/9
Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference
18.3%
5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%
10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%
4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%
12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%
1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%
8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%
1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%
10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%
7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%
5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%
10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%
4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%
12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%
1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%
8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%
1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%
10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%
7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%
TOP News Decliners
4/1
Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $35.00 price target on the stock.
-14.9%
12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%
3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%
3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%
2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%
2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%
4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%
2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%
4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%
8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%
12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%
3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%
3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%
2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%
2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%
4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%
2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%
4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%
8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: